Literature DB >> 32327718

Advancing scientific knowledge in times of pandemics.

Nicolas Vabret1, Robert Samstein2, Nicolas Fernandez2, Miriam Merad2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32327718      PMCID: PMC7187143          DOI: 10.1038/s41577-020-0319-0

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


× No keyword cloud information.
Since its reported emergence in Wuhan, China, in December 2019, the fast-growing pace of the COVID-19 pandemic has been challenging the capacities of health-care systems worldwide. Our research institute, the Precision Immunology Institute at the Icahn School of Medicine (PrIISM) is located within the Mount Sinai Health System in New York, a city that is disproportionately affected by COVID-19. With non-COVID-19 research being progressively halted, several immunology laboratories here have started to address COVID-19-related research efforts, such as studying the interactions of SARS-CoV-2 with the immune system, understanding the immunopathology that it causes, and developing new therapies and vaccine strategies against the virus. In parallel to these research programmes, we initiated an institutional effort to provide critical reviews of COVID-19 articles posted daily on the preprint servers bioRxiv and medRxiv[1], which we call the Sinai Immunology Review Project. This effort was designed to meet two needs. The first is a desire from our students, postdocs, fellows and faculty members to contribute to the global research effort and harness their knowledge and skills to help the scientific community. The second stems from a challenging consequence of the growing importance of preprints in scientific communication. The swift and open dissemination of information offered by preprints has already proved crucial in providing rapid scientific responses to the emerging public threat of viral outbreaks[2,3]. However, the ambition of preprint servers was never to replace the peer-review process. The spread of the COVID-19 pandemic has been matched by an impressive rise in related publications in both preprint servers and peer-reviewed journals. At a time when journal editors and invited reviewers are more solicited than ever, we decided that it is the responsibility of the scientific community to help curate this unprecedented flow of scientific data. Reviewing preprints benefits both the authors and the scientific community and provides the general public with access to scientific discussion, helping to reinforce scientific credibility[4]. Our workflow ranks each COVID-19-related preprint (totalling 1,772 to date) according to its immunological relevance. The most relevant papers are then reviewed in detail by trainees and validated by a faculty member. Validated reviews (118 to date) are then posted alongside the corresponding article on the preprint server. A PrIISM scientist, Nicolas Fernandez, built a dedicated website to host and integrate all of our reviews (see Related links), which are further shared with other pre-publication reviewing initiatives[4]. We have also launched a collaboration with Nature Reviews Immunology to publish short summaries of preprints of particular interest in a weekly column. Despite its flaws, peer-reviewing is an integral part of a scientist’s mission to the academic community and to the public. Jean Monet, one of the founding fathers of the European Union, stated: “People only accept changes in necessity and see necessity only in crisis”[5]. The COVID-19 pandemic and its prolific scientific response provide a unique opportunity for our community to experiment with new methods of peer-reviewing scientific communications at scale, and the Sinai immunology community is stepping up to the challenge.
  21 in total

1.  The evolving role of preprints in the dissemination of COVID-19 research and their impact on the science communication landscape.

Authors:  Nicholas Fraser; Liam Brierley; Gautam Dey; Jessica K Polka; Máté Pálfy; Federico Nanni; Jonathon Alexis Coates
Journal:  PLoS Biol       Date:  2021-04-02       Impact factor: 8.029

Review 2.  Immunology of COVID-19: Current State of the Science.

Authors:  Nicolas Vabret; Graham J Britton; Conor Gruber; Samarth Hegde; Joel Kim; Maria Kuksin; Rachel Levantovsky; Louise Malle; Alvaro Moreira; Matthew D Park; Luisanna Pia; Emma Risson; Miriam Saffern; Bérengère Salomé; Myvizhi Esai Selvan; Matthew P Spindler; Jessica Tan; Verena van der Heide; Jill K Gregory; Konstantina Alexandropoulos; Nina Bhardwaj; Brian D Brown; Benjamin Greenbaum; Zeynep H Gümüş; Dirk Homann; Amir Horowitz; Alice O Kamphorst; Maria A Curotto de Lafaille; Saurabh Mehandru; Miriam Merad; Robert M Samstein
Journal:  Immunity       Date:  2020-05-06       Impact factor: 31.745

Review 3.  Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction.

Authors:  Paolo Severino; Andrea D'Amato; Mariateresa Pucci; Fabio Infusino; Francesco Adamo; Lucia Ilaria Birtolo; Lucrezia Netti; Giulio Montefusco; Cristina Chimenti; Carlo Lavalle; Viviana Maestrini; Massimo Mancone; William M Chilian; Francesco Fedele
Journal:  Int J Mol Sci       Date:  2020-10-30       Impact factor: 6.208

Review 4.  COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds.

Authors:  John P Moore; P J Klasse
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

5.  Mild anemia as a single independent predictor of mortality in patients with COVID-19.

Authors:  Douglas Tremblay; Joseph L Rapp; Naomi Alpert; Wil Lieberman-Cribbin; John Mascarenhas; Emanuela Taioli; Saghi Ghaffari
Journal:  EJHaem       Date:  2021-05-06

6.  Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.

Authors:  Aymeric Silvin; Nicolas Chapuis; Garett Dunsmore; Anne-Gaëlle Goubet; Agathe Dubuisson; Lisa Derosa; Carole Almire; Clémence Hénon; Olivier Kosmider; Nathalie Droin; Philippe Rameau; Cyril Catelain; Alexia Alfaro; Charles Dussiau; Chloé Friedrich; Elise Sourdeau; Nathalie Marin; Tali-Anne Szwebel; Delphine Cantin; Luc Mouthon; Didier Borderie; Marc Deloger; Delphine Bredel; Severine Mouraud; Damien Drubay; Muriel Andrieu; Anne-Sophie Lhonneur; Véronique Saada; Annabelle Stoclin; Christophe Willekens; Fanny Pommeret; Frank Griscelli; Lai Guan Ng; Zheng Zhang; Pierre Bost; Ido Amit; Fabrice Barlesi; Aurélien Marabelle; Frédéric Pène; Bertrand Gachot; Fabrice André; Laurence Zitvogel; Florent Ginhoux; Michaela Fontenay; Eric Solary
Journal:  Cell       Date:  2020-08-05       Impact factor: 41.582

Review 7.  Targeting the NLRP3 Inflammasome in Severe COVID-19.

Authors:  Tracey L Freeman; Talia H Swartz
Journal:  Front Immunol       Date:  2020-06-23       Impact factor: 7.561

8.  Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I-conceptual challenges.

Authors:  Sergio Rutella; Michael A Cannarile; Sacha Gnjatic; Bruno Gomes; Justin Guinney; Vaios Karanikas; Mohan Karkada; John M Kirkwood; Beatrix Kotlan; Giuseppe V Masucci; Els Meeusen; Anne Monette; Aung Naing; Vésteinn Thorsson; Nicholas Tschernia; Ena Wang; Daniel K Wells; Timothy L Wyant; Alessandra Cesano
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

9.  Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic.

Authors:  Silvia Gianola; Tiago S Jesus; Silvia Bargeri; Greta Castellini
Journal:  PLoS One       Date:  2020-10-06       Impact factor: 3.240

Review 10.  Considerations for diagnostic COVID-19 tests.

Authors:  Olivier Vandenberg; Delphine Martiny; Olivier Rochas; Alex van Belkum; Zisis Kozlakidis
Journal:  Nat Rev Microbiol       Date:  2020-10-14       Impact factor: 78.297

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.